Cimduo (lamivudine and tenofovir disoproxil fumarate) is expected to be a more affordable tenofovir-based HIV product costing approximately $12,000 per year (wholesale acquisition cost).

For more information see Cimduo Prices, Coupons and Patient Assistance Programs

Cimduo contains lamivudine 300 mg and tenofovir disoproxil fumarate 300 mg and is a combination agent used with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 infection (HIV-1 infection).

According to the Fair Pricing Coalition, Cimduo's list price is expected to run 40% lower than other comparable agents currently on the market.

Cimduo, from Mylan, is predicted to compete with Truvada (emtricitabine and tenofovir disoproxil) and Descovy (emtricitabine and tenofovir alafenamide and), other HIV drugs, both from Gilead.

Unlike Truvada and Descovy, Cimduo is not approved by the FDA for use as pre-exposure prophylaxis (PrEP) to prevent HIV infection.